scholarly journals MAIN ASPECTS AND RESULT’S TREATMENT OF PRIMARY MEDIASTINAL B-CELL LARGE LYMPHOMA

2021 ◽  
Vol 22 (1) ◽  
pp. 59-71
Author(s):  
J.N. Vinogradova ◽  
V.V. Rjabchikova ◽  
A.I. Chumachenko ◽  
E.V. Karjagina ◽  
N.V. Medvedeva ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
B Cell ◽  
Proper Time ◽  
Long Term Results ◽  
Negative Data ◽  
First Line ◽  
Prognostic Sign

Efficiency of first-line immunopolychemotherapy schemes was comparable. Long-term results were better with immunochaemoradiotherapy; the presence of PET-negative data after the first line of immunopolychemotherapy is a favourable prognostic sign. Radiation therapy executed in proper time helps to reduce the systemic cytostatic stress.

Long-term results of hepatic artery fluorodeoxyuridine and conformal radiation therapy for primary hepatobiliary cancers

1997 ◽  
Vol 37 (2) ◽  
pp. 325-330 ◽  
Author(s):  
John M. Robertson ◽  
Theodore S. Lawrence ◽  
James C. Andrews ◽  
Suzette Walker ◽  
Marc L. Kessler ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Hepatic Artery ◽  
Long Term Results ◽  
Conformal Radiation Therapy

scholarly journals The first-line therapy of aggressive non-Hodgkin’s lymphomas in russian clinical practice: data from the EQUILIBRIUM study

2020 ◽  
Vol 15 (2) ◽  
pp. 10-18
Author(s):  
L. G. Babicheva ◽  
I. V. Poddubnaya
Keyword(s):  
Overall Survival ◽  
Clinical Practice ◽  
Complete Remission ◽  
B Cell ◽  
Long Term Results ◽  
First Line ◽  
Therapy Efficacy ◽  
First Line Therapy ◽  
Line Therapy ◽  
Hodgkin's Lymphomas

The objective: evaluation of effectiveness of the first-line therapy with rituximab of B-cell lymphoproliferative diseases in Russian clinical practice in the period from 2014 to 2017.Materials and methods. The EQUILIBRIUM post-registration multicenter study included 1000 patients aged 21 to 91 years old with a verified diagnosis of B-cell non-Hodgkin’s lymphoma, or chronic lymphocytic leukemia, who received at least 4 cycles of rituximab-containing therapy with Acellbia®. The group of aggressive non-Hodgkin’s lymphomas (aNHL), which is the subject of this article, included 295 patients with a median age of 55.9 years: diffuse B-large cell lymphoma – 87 %, primary mediastinal lymphoma – 11 %, Burkitt’s lymphoma – 1 %. Group characterized by the presence of aggressive clinical signs reflecting the poor prognosis: in the majority of patients, generalized stages were diagnosed (61 %), in half of the cases (50.2 %), extranodal localization of tumor foci was detected (in 32.4 % of patients there were 2 or more). The overwhelming majority of patients (84.5 %) received adequate treatment complying with national and international recommendations (R-CHOP, R-CHOEP and R-EPOCH, high-intensity NHL-BFM-R, R-HyperCVAD and R-MACOP-B regimes). The use of R-CVP, FCR, RB, Chl-R, R-monotherapy treatment programs (which received 15.5 % of patients) was considered inadequate for this category of patients.Results. According to the results of the final assessment, high therapy efficacy was established: the overall response exceeded 90 %, complete remission was achieved in most patients with aNHL (68.5 %), partial remission – in every 5th patient (21.8 %). With a median follow-up of 15 months, 16 (5.42 %) deaths and 34 (11.53 %) events were registered. Median of event-free survival and overall survival have not been achieved. Statistically significant differences depending on first-line therapy efficacy were found in overall survival (p = 0.00000) and eventfree survival (p = 0.00000), once again confirming that the main goal of aNHL treatment is to achieve complete remission.Conclusion. Available and compliant with national clinical guidelines treatment of aNHL patients with Russian bioanalogue of anti-CD20 monoclonal antibodies (Acellbia®) demonstrates high immediate efficacy and acceptable long-term results, comparable to a retrospective analysis of previous clinical studies of the original drug rituximab.

scholarly journals Heart valve injury due to radiation therapy

Kardiologiia ◽  
2019 ◽  
Vol 59 (2S) ◽  
pp. 56-68
Author(s):  
M. G. Poltavskaya ◽  
E. I. Emelina ◽  
Yu. V. Avdeev ◽  
G. E. Gendlin ◽  
G. N. Paramonova
Keyword(s):  
Radiation Therapy ◽  
Heart Valves ◽  
Single Photon ◽  
Stress Test ◽  
Gas Analysis ◽  
Long Term Results ◽  
Cardiovascular Pathology ◽  
Results Of Treatment ◽  
Clinically Significant

Relevance.Radiation therapy (RT) plays an important role in oncology, improving the immediate and long-term results of treatment of a number of tumors. One of the most significant complications of RT are lesions of the heart valves.Objective.To study the variants of valve damage that occur in patients who received radiation therapy for cancer.Patients and methods.A group of patients who, during the period from 1978 to 2002, underwent chemo-radiation therapy (CRT) for Hodgkin's lymphoma (LH) of 2–4 stages with damage to the intrathoracic lymph nodes: 71 patients, 60 of whom did not go to the cardiologist and were invited to be examined, 11 were hospitalized due to clinically significant cardiovascular pathology (CHF, myocardial infarction, angina pectoris, valvular defect, AV block). The study methods included: standard clinical and laboratory examination, spirometry, 24‑hour ECG monitoring, echocardiography, in some patients single-photon myocardial emission tomoscintigraphy (SPECT), and CT scan of the chest organs. In 60 patients, a stress test on an ECG-controlled treadmill was performed, in 18 patients – a maximum stress test on a treadmill with a gas analysis – ergospirometry.Results and discussion. Valve pathology was detected in 49.3 % of cases, most often (in 46.5 %) mitral regurgitation (MR) occurred, primarily due to MR of the 1 st degree, which had no clinical significance. Pathology of the aortic valve (12.7 % of patients) was represented mainly by mild regurgitation (11.3 %). Aortic stenosis was diagnosed in 4.2 % of patients. In the studied cohort of patients, predominantly non-severe valve lesions were detected. In addition, examples of patients with clinically significant valve valvular lesions are presented.

Long-Term Results After Intraoperative Radiation Therapy for Gastric Cancer

2008 ◽  
Vol 70 (3) ◽  
pp. 715-721 ◽  
Author(s):  
Oliver Drognitz ◽  
Karl Henne ◽  
Christian Weissenberger ◽  
Gregor Bruggmoser ◽  
Heike Göbel ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Radiation Therapy ◽  
Long Term Results ◽  
Intraoperative Radiation Therapy ◽  
Intraoperative Radiation

Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD.

1997 ◽  
Vol 15 (2) ◽  
pp. 528-534 ◽  
Author(s):  
V Bonfante ◽  
A Santoro ◽  
S Viviani ◽  
L Devizzi ◽  
M Balzarotti ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Complete Remission ◽  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Response Duration ◽  
Long Term Results ◽  
High Dose ◽  
First Line ◽  
Disease Extent

PURPOSE This study analyzed long-term results in patients with Hodgkin's disease who were resistant to or relapsed after first-line treatment with MOPP and ABVD. Response to salvage treatments and prognostic factors were also evaluated. PATIENTS AND METHODS The study population included 115 refractory or relapsed patients among a total of 415 patients treated with alternating or hybrid MOPP-ABVD followed by radiotherapy (25 to 30 Gy) to initial bulky sites. The median follow-up duration of the present series was 91 months. Thirty-nine of 115 patients (34%) showed disease progression while on primary treatment (induction failures); 48 relapsed after complete remissions that lasted < or = 12 months and 28 after complete remission that lasted more than 12 months from the end of all treatments. RESULTS At 8 years, the overall survival rate was 27%, being 54% and 28% in patients whose initial complete remission was longer or shorter than 12 months, respectively, and 8% in induction failures (P < .001). Response to first-line chemotherapy and disease extent at first progression significantly influenced long-term results, as well as the incidence and duration of complete remission. CONCLUSION The present data confirm previous observations that showed the main prognostic factors to influence outcome after salvage treatment are response duration to first-line therapy and disease extent at relapse. The results indicate that patients who relapse after the alternating MOPP/ABVD regimen have a prognosis similar to that of patients who relapse after a four-drug regimen (MOPP or ABVD alone). Re-treatment with initial chemotherapy seems the treatment of choice for patients who relapse after an initial complete remission that lasts greater than 12 months, while the real impact of high-dose chemotherapy or new regimens should be assessed in resistant patients.

Sign in / Sign up

Export Citation Format

Share Document